Ligand Pharmaceuticals Inc - Class B

NASDAQ: LGND
$121.25
-$8.65 (-6.7%)
Closing Price on November 8, 2024

LGND Stock Chart and Intraday Price

LGND Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,372.21M USD
Shares Outstanding 17,436,000
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and licensing a diverse portfolio of therapeutic products. It has a range of treatments for multiple myeloma, acute lymphoblastic leukemia, rare kidney diseases, osteoporosis, and pneumococcal diseases among others. Its products include Kyprolis, Evomela, Rylaze, and Veklury for COVID-19 treatment. The company collaborates with industry giants like Amgen, Merck, and Pfizer, providing innovative solutions such as Captisol technology for drug formulation. Founded in 1987, Ligand is headquartered in Jupiter, Florida, contributing to healthcare advancements globally.

LGND Articles

Here is a look at how shares of FuelCell Energy, Gilead Sciences, Starbucks and more have fared since their initial public offerings in 1992.
Tuesday's top analyst upgrades and downgrades included Array Technologies, CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Intercontinental Exchange, Medical Properties Trust, Paramount...
Short sellers seem to have many emerging and speculative biotech stocks targeted for termination. Here are eight of them against which short sellers are betting the farm.
In a new research report, RBC did some intense digging in the small-cap arena and came up with some fascinating research. These are five top small-cap growth plays suited for aggressive accounts.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Activision Blizzard, Biogen, Deere, DocuSign, Ford, Freeport-McMoRan, General Motors, Lattice Semiconductor, Qualys,...
Nordstrom, Tailored Brands, Electronics for Imaging and Ligand Pharmaceuticals had all posted new 52-week lows by noon Wednesday.
The top analyst upgrades, downgrades and other research calls from Monday included Amazon.com, Anheuser-Busch Inbev, Caterpillar, HUYA, Ligand Pharmaceuticals, Verizon and Weyerhaeuser.
The top analyst upgrades, downgrades and other research calls from Friday include DSW, Dean Foods, Fluor, JD.com, Nvidia, Viper Energy and Walmart.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Barrick Gold, Caterpillar, ConocoPhillips, PNC Financial, Tonix Pharmaceuticals and Spirit Realty.
Insider selling is likely to keep ramping higher, as many on Wall Street see volatility going higher this summer as we get closer to the political cycle home stretch.
We mentioned often that the market has not seen a 10% correction for three years. This week's selling may very well get that talking point off the books and set the stage for a solid run to the end...
Monday's top analyst upgrades, downgrades and initiations include EMC, Herbalife, Micron Technology, Petrobras and SanDisk.
via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other, and now we have another impending government shutdown. The reality is that some...
August 2, 2013: U.S. equity markets opened lower this morning following a mixed report on U.S. employment. The monthly report on personal income and outlays was also a mixed bag, with core prices...
Jon OggIt is Friday and the markets have another monthly employment report to absorb, but Wall Street analysts also have many research calls that have been made. 24/7 Wall St. reviews many fresh...